Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Saved in:
| Title: | Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. |
|---|---|
| Authors: | Fizazi, Karim1 (AUTHOR) karim.fizazi@gustaveroussy.fr, Tran, NamPhuong2 (AUTHOR), Fein, Luis3 (AUTHOR), Matsubara, Nobuaki4 (AUTHOR), Rodriguez-Antolin, Alfredo5 (AUTHOR), Alekseev, Boris Y6 (AUTHOR), Özgüroğlu, Mustafa7 (AUTHOR), Ye, Dingwei8 (AUTHOR), Feyerabend, Susan9 (AUTHOR), Protheroe, Andrew10 (AUTHOR), Sulur, Giri2 (AUTHOR), Luna, Yesenia2 (AUTHOR), Li, Susan11 (AUTHOR), Mundle, Suneel12 (AUTHOR), Chi, Kim N13 (AUTHOR) |
| Source: | Lancet Oncology. May2019, Vol. 20 Issue 5, p686-700. 15p. |
| Database: | Academic Search Ultimate |
| ISSN: | 14702045 |
|---|---|
| DOI: | 10.1016/S1470-2045(19)30082-8 |
